Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?

9Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Neuropeptide S (NPS) is a neuropeptide primarily produced within three brainstem regions including locus coeruleus, trigeminal nerve nucleus, and lateral parabrachial nucleus. NPS is involved in the central regulation of stress, fear, and cognitive integration. NPS is a mediator of behavior, seeking food, and the proliferation of new adipocytes in the setting of obesity. So far, current research of NPS is only limited to animal models; data regarding its functions in humans is still scarce. Animal studies showed that anxiety and appetite might be suppressed by the action of NPS. The discovery of this neuromodulator peptide is effective considering its strong anxiolytic action, which has the potential to be an interesting therapeutic option in treating neuropsychiatric disorders. In this article, we aimed to analyze the pharmaceutical properties of NPS as well as its influence on several neurophysiological aspects—modulation of behavior, association with obesity, as well as its potential application in rehabilitation and treatment of psychiatric disorders.

Cite

CITATION STYLE

APA

Markiewicz-Gospodarek, A., Kuszta, P., Baj, J., Dobrowolska, B., & Markiewicz, R. (2022, April 26). Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders? Frontiers in Public Health. Frontiers Media S.A. https://doi.org/10.3389/fpubh.2022.872430

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free